Print this article
- 07/01/2022

VTAMA® (tapinarof) cream, 1% PSOARING 3 Final Data Published in JAAD

HPC Today

LONG BEACH, Calif., and BASEL, Switzerland, June 28, 2022—Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that new data from the one-year safety and efficacy final analyses of the Phase 3 PSOARING 3 long-term, open-label extension (“LTE”) study of VTAMA® (tapinarof) cream,


“We are excited that a journal as prestigious as JAAD has chosen to publish final data from our PSOARING 3 40-week extension efficacy and safety study of VTAMA® (tapinarof) cream,


Newly published final data in JAAD includes efficacy outcomes, quality of life, safety, and tolerability assessments observed over long-term use of VTAMA® (tapinarof) cream,


On May 24, Dermavant announced that the FDA had approved VTAMA (tapinarof) cream,